약물 남용 치료 시장 : 시장 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The substance drug abuse treatment market size is valued at USD 11.75 billion in 2025 and is forecast to reach USD 15.35 billion by 2030, advancing at a 5.5% CAGR.

Growth rests on unprecedented public-sector funding such as the USD 46.8 million behavioral-health grants announced in May 2024; and regulatory modernization that removed the Drug Addiction Treatment Act waiver in October 2024, letting any qualified clinician prescribe buprenorphine. These forces are re-shaping competitive strategy: technology firms now partner with clinics to deploy FDA-cleared prescription digital therapeutics, while insurers rapidly widen reimbursement under the parity rules that came into full effect in January 2025. Asia-Pacific's 7.15% CAGR underlines a pivot from infrastructure building to integrated care, showcased by China's 191 detoxification pilots that treated 1.7 million people by end-2023.

Global Substance Abuse Treatment Market Trends and Insights

Rising Prevalence of Opioid & Alcohol Use Disorders

In 2023, 48.5 million Americans aged 12 or older had a substance use disorder, but only 23.6% accessed treatment. The resulting treatment gap fuels sustained demand as policymakers shift from punitive to medical models. Younger demographics intensify service redesign, illustrated by China's youth-focused detoxification centers. Polysubstance fatalities-particularly stimulants co-used with opioids-necessitate protocols that address multiple dependencies at once. The WHO's updated opioid-dependence guidelines, scheduled for October 2025, elevate opioid agonist maintenance to global standard of care.

Expansion of Insurance & Government Funding

Parity enforcement effective January 2025 obliges U.S. health plans to prove equal coverage for behavioral care, removing prior-authorization hurdles for addiction treatment. Complementing regulation, the Biden administration's USD 1.48 billion State Opioid Response grants emphasize evidence-based practice and underserved communities. Internationally, WHO's May 2025 controlled-medicine guidance pushes low- and middle-income countries to balance opioid access and diversion control.

Social Stigma Limiting Treatment Uptake

94.7% of U.S. adults with a substance use disorder do not seek care, chiefly because they deny a need for treatment despite clinical criteria. Stigma is deeply cultural: Asian clients often avoid formal programs to protect family reputation, pushing providers to adopt family-oriented and community-based models. Digital anonymity helps but cannot fully erase entrenched attitudes.

Other drivers and restraints analyzed in the detailed report include:

1. Wider Adoption of Medication-Assisted Treatment (MAT)
2. Employer-Sponsored Recovery Benefits
3. Shortage of Certified Addiction Specialists

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Pharmacotherapy remains the largest revenue generator, holding 43.65% of substance drug abuse treatment market share in 2024. Methadone, buprenorphine, and extended-release naltrexone anchor clinical guidelines and receive widening reimbursement under parity enforcement. Digital therapeutics, however, is the fastest climber at 6.45% CAGR through 2030. FDA-cleared apps such as reSET-O pair cognitive behavioral therapy with real-time adherence tracking, permitting clinicians to monitor dosage logs and craving scores remotely. Insurers increasingly bundle software prescriptions with medication bills, ensuring revenue capture without direct facility expansion. Behavioral therapy retains relevance as the human connective tissue that sustains engagement and addresses trauma; culturally-tailored cognitive restructuring is critical for younger cohorts and minority groups whose relapse triggers differ from historical norms. The substance drug abuse treatment market benefits from converging data streams-wearable biosignals, electronic health record (EHR) alerts, and patient-reported outcomes-that feed predictive analytics. NIH-supported pilots show AI-driven dashboards reduce hospital readmissions, reinforcing payers' interest in data-validated interventions. Downstream, combination protocols-long-acting injectable buprenorphine plus prescription digital therapeutic coaching-signal a hybrid future where care teams orchestrate medication, software, and counseling into a singular treatment pathway.

A parallel monetization shift is unfolding. Software-as-a-medical-device (SaMD) companies license platforms to health systems, collecting per-member-per-month fees rather than episodic therapy margins. Pharma firms are co-packaging adherence apps with new formulations, betting that digital support will boost refill persistence and protect patent value. Investors deem the blended model more defensible than stand-alone clinics, amplifying merger activity between tele-MAT providers and analytics startups. This synergy underlines how the substance drug abuse treatment market is migrating from unit-based payments toward longitudinal value contracts tied to relapse-free days and workforce productivity metrics.

Outpatient programs provided 52.35% of total revenue in 2024, driven by clinical guidelines that favor continuous, community-based MAT over expensive inpatient stays. The DEA's telemedicine flexibility-now extended through December 2025-lets clinicians prescribe buprenorphine after virtual evaluation, collapsing geographical barriers and accelerating telehealth uptake at a 7.01% CAGR. Clinics re-engineer workflows for hybrid care: initial stabilization may occur onsite, followed by digital check-ins, synchronous therapy, and asynchronous medication refills. Research funded by HHS confirms tele-MAT maintains parity with in-person retention and satisfaction scores.

Cost dynamics reinforce the trend. Payers observe that a 12-week virtual intensive outpatient episode costs materially less than residential admission yet yields equivalent abstinence days. Providers leverage remote urine-drug testing kits and computer-vision pill counts to satisfy compliance audits. Rural health systems capitalize by embedding addiction specialists via e-consult portals, bypassing recruitment bottlenecks. The substance drug abuse treatment market size for hybrid outpatient services is projected to expand at 6.8% annually, reflecting payer preference for capitated models that bundle telehealth, pharmacy, and lab services. Brick-and-mortar operators respond by converting under-utilized beds into community hubs for group therapy and peer-led recovery coaching, aligning physical assets with digital service layers.

The Substance Abuse Treatment Market Report Segments the Industry Into by Treatment Type (Pharmacotherapy, Behavorial Therapy and More), by Treatment Setting (Inpatient/Residential, Outpatient), by Substance Dependency (Alcohol Use Disorder, Opioid Use Disorder and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America captured 44.32% of total revenue in 2024, underpinned by mature insurance coverage, robust prescribing capacity, and prompt adoption of FDA-authorized digital therapeutics. The Mental Health Parity Act's 2025 enforcement milestone compels commercial plans covering 175 million lives to remove non-quantitative limits such as fail-first policies, immediately lifting utilization ceilings. Federal funding remains pivotal: USD 1.48 billion in State Opioid Response grants finance naloxone distribution, peer recovery coaches, and mobile MAT units in high-overdose counties. Canada's publicly-funded systems lag in digital-therapy reimbursement yet pioneer safe-supply pilots, while Mexico expands cross-border tele-MAT partnerships to reach remote regions.

Asia-Pacific is the fastest-growing territory, advancing at 7.15% CAGR through 2030. China's deployment of 191 detoxification centers serving 1.7 million patients by end-2023 exemplifies state-driven infrastructure scaling globaltimes.cn. Australia introduces nurse-prescribing of buprenorphine in rural zones, easing workforce scarcity. India confronts fentanyl spill-over risks, prompting draft rules for precursor surveillance and joint task forces with WHO. However, digital mental-health access gaps persist; broadband penetration and mental-health literacy remain uneven, necessitating mobile-first solutions and culturally-adapted content in local languages.

Europe occupies a middle ground, boasting universal coverage but facing fragmented reimbursement for digital therapeutics. Germany's DiGA framework fast-tracks software-as-a-medical-device reimbursement, yet addiction apps constitute only 4% of listings. Workforce shortages-particularly psychiatrists trained in addiction-slow throughput in rural Scandinavia and Eastern Europe. Middle East & Africa show nascent yet accelerating demand; Saudi Arabia funds medically-supervised detox centers as part of Vision 2030, while South Africa pilots community-based harm-reduction projects aligned with WHO guidelines. Regional heterogeneity underscores the need for adaptable, evidence-backed models within the substance drug abuse treatment market.

1. AstraZeneca
2. Merck
3. Roche
4. Bristol-Myers Squibb
5. Novartis
6. Pfizer
7. Eli Lilly and Company
8. Amgen
9. BeiGene
10. Takeda Pharmaceuticals
11. Regeneron
12. Sanofi
13. Daiichi Sankyo
14. Johnson & Johnson
15. Boehringer Ingelheim
16. Innovent Biologics
17. Exelixis
18. Mirati Therapeutics
19. Blueprint Medicines
20. Zai Lab

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Check-point inhibitor dominance in 1L metastatic setting
  • 4.2.2 Rapid uptake of EGFR/ALK targeted therapies in resectable early-stage NSCLC
  • 4.2.3 Liquid-biopsy companion diagnostics adoption
  • 4.2.4 Radiopharmaceutical pipeline breakthroughs
  • 4.2.5 AI-guided trial design & faster FDA approvals
• 4.3 Market Restraints
  • 4.3.1 Price caps & HTA push-backs in Europe
  • 4.3.2 Diagnostic biomarker testing capacity gaps in emerging Asia
  • 4.3.3 PD-(L)1 class saturation & payer rebate squeeze
  • 4.3.4 Manufacturing bottlenecks for ADC payloads
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Histology
  • 5.1.1 Adenocarcinoma
  • 5.1.2 Squamous Cell Carcinoma
  • 5.1.3 Large Cell Carcinoma
• 5.2 By Treatment Modality
  • 5.2.1 Surgery
  • 5.2.2 Radiation Therapy
  • 5.2.3 Chemotherapy
  • 5.2.4 Targeted Therapy
  • 5.2.5 Immunotherapy
  • 5.2.6 Radiopharmaceuticals
• 5.3 By Drug Class
  • 5.3.1 EGFR TKIs
  • 5.3.2 ALK/ROS1/RET Inhibitors
  • 5.3.3 PD-1 / PD-L1 Inhibitors
  • 5.3.4 CTLA-4 & LAG-3 Inhibitors
  • 5.3.5 Antibody-Drug Conjugates (ADC)
• 5.4 By Region
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Spain
    • 5.4.2.5 Italy
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 AstraZeneca
  • 6.3.2 Merck & Co.
  • 6.3.3 F. Hoffmann-La Roche
  • 6.3.4 Bristol Myers Squibb
  • 6.3.5 Novartis
  • 6.3.6 Pfizer
  • 6.3.7 Eli Lilly
  • 6.3.8 Amgen
  • 6.3.9 BeiGene
  • 6.3.10 Takeda
  • 6.3.11 Regeneron
  • 6.3.12 Sanofi
  • 6.3.13 Daiichi Sankyo
  • 6.3.14 Johnson & Johnson
  • 6.3.15 Boehringer Ingelheim
  • 6.3.16 Innovent Biologics
  • 6.3.17 Exelixis
  • 6.3.18 Mirati Therapeutics
  • 6.3.19 Blueprint Medicines
  • 6.3.20 Zai Lab

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment